BJH - 2021, issue SPECIAL, january 2021
Prof J. Apperley
The therapeutic landscape of chronic myeloid leukaemia (CML) has changed dramatically over the past decades and the majority of patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP) now have a near-normal life expectancy.1 Based on two recent published guidelines (European LeukemiaNet (ELN) guideline1 and the British Society for Haematology guideline2) and the presentation by Prof. Jane Apperley during the 2021 BHS GAM, this article will give an overview of the latest developments in the therapeutic CML landscape and address a range of the persistent unmet needs in the diagnosis and treatment of CP-CML.
Read more
Top
